Anti-Cd7 chimeric antigen receptor natural killer cell therapy (PersonGen Biomedicine)

N/A

Report date: 2023/05/05 17:09:17

Base Information

Drug NameAnti-Cd7 chimeric antigen receptor natural killer cell therapy (PersonGen Biomedicine)
Drug Alias Name抗CD7嵌合抗原受体修饰自然杀伤细胞疗法（博生吉）CAR-pNK Cell immunotherapyanti-CD7 CAR-pNK cell therapyCAR-pNK (PersonGen Biomedicine)
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionT-cell antigen CD7 inhibitors
TargetsT-cell antigen CD7
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Extranodal NK-T-Cell +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Active IndicationsN/A
Inactive IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Extranodal NK-T-Cell +[9] 

Other Information

ATC CodeN/A
Related LinksN/A